Abstract

<h3>Objective:</h3> To explore how age influences sulfonylurea-receptor-1 (SUR1)-related genes and biological processes across cell subtypes of the murine brain by using single cell RNA sequencing (scRNA-Seq). <h3>Background:</h3> SUR1-inhibition therapy is a promising therapeutic strategy being evaluated in a phase-II trial to improve the secondary injuries after traumatic brain injury (TBI). The impact of this therapy may vary with age depending on related differences in gene expression/biological processes. <h3>Design/Methods:</h3> scRNA-Seq was performed on naïve murine brain at two adult ages (12wk=younger, 9mo=older). Individual cell types were annotated and SUR1-related differentially expressed genes (DEGs) were identified (MAST) and pathway activity was predicted (AUCell) based on 202 genes related to SUR1 identified a priori. Biological processes (gene-ontology, GOBP), lineage differentiation/pseudotime (Monocle2), and cell-communication (CellChat) were determined for the SUR1-related pathway. <h3>Results:</h3> 55,211 cells were sequenced (25,728=younger, 29,483=older), including 10 cell types and multiple subtypes. Cell subtype distribution varied with age including different subpopulations of microglia, astrocytes, ependymal, endothelial, and mural cells. Neuronal subtypes were similar between ages. Overall, SUR1-pathway activity was higher in older vs. younger mice (all celltypes). A high proportion of astrocytes and endothelial cells had increased SUR1-pathway activity in older mice. Variability in SUR1-pathway activity was seen across cell subtypes. Increased SUR1-pathway activity in microglia and endothelial cells of older mice was associated with alterations in neuronal synaptic plasticity and regulation of neurogenesis contrasting predominantly inflammatory responses in younger mice. Higher SUR1-pathway activity in neurons of older mice was associated with cell death pathways. The number, strength and diversity of cell-communication interactions was greater in younger vs older mice, particularly robust in cells with high levels of SUR1-pathway activity <h3>Conclusions:</h3> There are robust cell-specific age-based biological differences in SUR1-related pathway activity in murine brain. This may facilitate understanding of how this pathway relates to aging, as well as developing age-based therapeutic targets. <b>Disclosure:</b> Dr. Xiong has nothing to disclose. Mr. Sneiderman has nothing to disclose. Dr. Rajasundaram has nothing to disclose. Dr. Simon has nothing to disclose. Dr. Catapano has nothing to disclose. Mr. Rulney has nothing to disclose. Dr. Raikwar has nothing to disclose. Dr. Rani has nothing to disclose. Dr. Shahjouei has nothing to disclose. Mrs. Mihaljevic has nothing to disclose. Dr. Winkler has nothing to disclose. Ms. Feldman has nothing to disclose. Miss Trivedi has nothing to disclose. Vincent Vagni has nothing to disclose. Patrick M. Kochanek, MD, MCCM has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Johns Hopkins Health System. The institution of Patrick M. Kochanek, MD, MCCM has received research support from Chuck Noll Foundation. The institution of Patrick M. Kochanek, MD, MCCM has received research support from NIH. Patrick M. Kochanek, MD, MCCM has received publishing royalties from a publication relating to health care. Dr. Jha has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. An immediate family member of Dr. Jha has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Legal fees. The institution of Dr. Jha has received research support from NIH/NINDS, Chuck Noll Foundation, University of Pittsburgh, Barrow Neurological Foundation. The institution of Dr. Kohanbash has received research support from NIH.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call